イタリア - イタリア語 - Ministero della Salute

allergan spa -

イタリア - イタリア語 - Ministero della Salute

allergan spa -

イタリア - イタリア語 - Ministero della Salute

xcelens sa - prodotti riassorbibili per riempimento e ricostruzione

欧州連合 - イタリア語 - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenti antineoplastici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

イタリア - イタリア語 - Ministero della Salute

allergan industrie sas - prodotti riassorbibili per riempimento e ricostruzione

イタリア - イタリア語 - Ministero della Salute

allergan industrie sas - prodotti riassorbibili per riempimento e ricostruzione

イタリア - イタリア語 - Ministero della Salute

allergan industrie sas - prodotti riassorbibili per riempimento e ricostruzione

イタリア - イタリア語 - Ministero della Salute

allergan industrie sas - prodotti riassorbibili per riempimento e ricostruzione